20 articles
Takeda's Phase 1 trial evaluates the safety and tolerability of TAK-510, a novel injectable agent targeting nausea and vomiting, across escalating doses.
275-patient study tests novel liver-targeted therapy for NASH, a serious form of fatty liver disease affecting millions worldwide.
A completed RCT tests whether small-sided football sessions 3x/week improve glucose control and metabolic health in T2DM patients on GLP-1 and SGLT2 drugs.
Maastricht University investigated whether NA, NAM, and tryptophan together could restore mitochondrial function in physically compromised older adults.
411-person study shows digital insulin delivery system helps optimize glucose control through automated dose tracking and mobile integration.
Enanta Pharmaceuticals tests its FXR agonist EDP-305 in a completed Phase 2 randomized trial for non-alcoholic steatohepatitis.
A completed University of Michigan trial explored how aerobic exercise training alters RAGE-mediated inflammatory pathways in type 2 diabetic adults.
Carmot Therapeutics tests CT-868, a novel dual incretin receptor agonist, for HbA1c reduction in overweight and obese adults with poorly controlled T2DM.
84-person study reveals how targeted nutrition counseling impacts blood sugar, weight, and heart health in diabetic patients.
12-week resistance training study shows promise for managing diabetes and preventing muscle loss in older adults.
Mediterranean diet, resistance training, and diabetes medication combined to combat sarcopenia and improve metabolic health in older adults.
A Phase 2 trial tests a GalNAc-conjugated antisense therapy in familial partial lipodystrophy patients with dangerously high triglycerides.
Stanford study tests whether GLP-1 drug exenatide can restore insulin function and promote weight loss in people with prediabetes.
A completed OSU trial investigates whether short-term exercise training can restore impaired mitochondrial cleanup pathways in overweight and obese skeletal muscle.
University of Pennsylvania study tests behavioral tools to help people stick with time-restricted eating for blood pressure and weight management.
Four-year study examined whether metformin could protect blood vessels in people with metabolic syndrome beyond its diabetes benefits.
A completed trial investigates whether replenishing glutathione precursors can reverse metabolic dysfunction in elderly adults.
VA study tests whether combining lifestyle changes with metformin can reverse muscle loss and frailty in obese older adults.
Eli Lilly's phase 3 trial pits a novel weekly basal insulin against the gold-standard daily insulin degludec in type 1 diabetes patients.
20-week study reveals how sequencing HIIT and resistance training affects metabolic health in women with morbid obesity.
